YSOPIA Bioscience’s game-changing strategy is built around developing living single-strain biotherapies based on carefully selected keystone bacteria.
> Discover our approach
Yso1 is a clinical-stage development program harnessing the potential of Christensenella gut bacteria to treat metabolically unhealthy obesity. Our flagship oral biotherapy Xla1 is based on a unique living bacterial strain naturally present in a healthy human gut microbiome: Christensenella minuta.
After demonstrating strong efficacy results in preclinical animal models, YSOPIA successfully completed the Phase 1 clinical study for its Xla1 biotherapy in July 2021 and demonstrated its excellent safety and tolerability profile, as well as first efficacy results.
Following this success, YSOPIA is preparing to launch a Phase 2 clinical trial to establish the first proof of concept for Christensenella’s efficacy in humans in treating obesity and its associated metabolic abnormalities.
This is built on our seminal work published in Cells (Mazier et al. 2021) demonstrating in vivo that our clinical candidate Xla1 limits body weight gain and normalizes several metabolic markers.
Yso2 is a preclinical program targeting Crohn’s disease. It aims to develop Christensenella gut bacteria as a safe, efficient and groundbreaking oral biotherapy.
YSOPIA has demonstrated the potent immunomodulatory properties of Christensenella both in vivo and in vitro, and underscored its potential for use in innovative microbiome-based IBD biotherapies.
Discover our work published in Scientific Reports (Kropp et al. 2021). Our team has selected from our proprietary strain library a lead candidate with strong in vitro and in vivo data package that makes it highly promising for human clinical studies.
Yso3 is a preclinical drug development program aimed at treating asthma. Using a revolutionary form of living biotherapy targeting the lung, YSOPIA is pioneering the innovative field of the lung microbiome.
As part of this program, YSOPIA has selected a clinical candidate having demonstrated strong in vivo efficacy on inflammation and lung functions.
We have achieved the formulation feasibility and cleared the regulatory hurdles associated with developing this new biotherapy. Continue our development plan to the clinical phase is the further step for this program.
Yso4 is an exploratory program targeting the gut-brain axis for the treatment of mood disorders.
Over the last 5 years, there has been increasing evidence that the gut microbiome is associated with neurological and behavioral disorders, in what is known as the “gut-brain axis”.
Multiple complex mechanisms of action are at play in this relationship, and although there is still much to discover, there is strong evidence that the gut microbiome affects neurotransmitter metabolism and neuroinflammation.
YSOPIA Bioscience has therefore launched research in this exciting area to harness the potential of carefully selected bacteria strains of Christensenellaceae to treat mood disorders such as depression and anxiety.
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs.
The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of these cancer immunotherapies.
YSOPIA is exploring the role of specific keystone bacteria with high therapeutic potential in the oncology field based on a strong understanding of their mechanisms of action.